Unresectable Malignant Solid Neoplasm clinical trials in Florida

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

DS-8201a plus olaparib for HER2-positive platinum-resistant ovarian cancer

This trial tests whether combining DS-8201a with olaparib can slow or shrink HER2-positive ovarian cancer that has returned quickly after platinum chemotherapy. It’s a Phase 1 study, meaning it mainly checks safety and finds the best dose, while also looking for signs of anti-cancer activity.

Testing a new drug combination for advanced solid tumors

This trial is studying whether a new combination of two cancer drugs, ZEN003694 and talazoparib, can help people with advanced solid tumors that have not responded to other treatments. Talazoparib is a type of drug that targets cancer cells with certain DNA repair problems. The study is divided into groups based on specific gene mutations or previous treatment responses.

Find targeted cancer treatments using genetic testing

This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.

Testing trastuzumab deruxtecan and neratinib for HER2-positive cancers

This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.

Entinostat plus ZEN003694 for advanced solid tumors

This Phase 1/2 study tests a new combination anti-cancer treatment (entinostat plus ZEN003694) in people with advanced solid tumors that can’t be controlled with standard care. It aims to find a safe dose and see whether the treatment can shrink tumors or control the disease.

Adding a new drug to capecitabine for metastatic colorectal cancer

This Phase 1 study tests a new anti-cancer drug (ZEN003694) added to the usual chemotherapy capecitabine. It is for adults with colorectal cancer (and possibly other cancers) that has spread or cannot be removed and has continued despite prior standard treatment.

Testing a new drug for advanced solid cancers

This trial tests a new drug (MTI-301) for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and shrinks tumors.

Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors

This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.

Study of MK-3120 for advanced solid tumors

This trial tests an investigational drug called MK-3120 for people with advanced solid tumors (cancer that has spread or cannot be removed). It is for patients whose cancer has progressed after standard treatments, and it aims to see if the drug is safe and effective.

Nivolumab at home vs. clinic for cancer treatment

This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.

T cell activator STAR0602 for advanced solid tumors

This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.

A study of MK-5684 for certain solid tumors

This trial tests an investigational drug called MK-5684 for people with specific types of breast, ovarian, or endometrial cancer. It aims to see if this treatment can help shrink or control the cancer when standard treatments have stopped working or are no longer effective.

Testing a new drug for breast cancer and other solid tumors

This trial tests a new oral drug (BGB-43395) alone or with other treatments for people with advanced breast cancer or other solid tumors that depend on CDK4. It aims to find safe doses and see if the drug helps shrink tumors or slow growth.

Study of SGN-CEACAM5C for advanced solid tumors

This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.

CAR T cell therapy for mesothelin-positive solid tumors

This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.

Study of JNJ-95437446 for advanced solid tumors

This trial tests a new drug, JNJ-95437446, in people with certain advanced cancers (non-small cell lung, colorectal, or head and neck cancer). The goal is to see if it can help shrink or control the cancer.

Test apheresis for CAR T manufacturing in HLA-A2 solid tumors

This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.

Study of a new treatment for advanced cancers with a specific gene change

This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.

Study of NKT3964 for advanced solid tumors

This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.

Sigvotatug vedotin for advanced solid tumors that spread

This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.

Test of an EGFR-targeting drug for advanced solid cancers

This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.